Efficacy of edelfosine lipid nanoparticles in breast cancer cells

Breast cancer is a heterogeneous group of neoplasms predominantly originating in the terminal duct lobular units. It represents the leading cause of cancer death in women and the survival frequencies for patients at advanced stages of the disease remain low. New treatment options need to be research...

Full description

Bibliographic Details
Authors: Aznar, M.A. (María Ángela)|||/items/8a93c205-a638-4589-8774-64166348f62c, Lasa-Saracibar, B. (Beatriz)|||/items/01d03220-3bc2-4e01-8b38-247a935720cd, Estella-Hermoso-de-Mendoza, A. (Ander)|||/items/a707a792-b20f-4871-9546-bd9aff90b5c5, Blanco-Prieto, M.J. (María José)|||/items/93e177db-635f-456f-b672-b79ef8befc40
Format: article
Publication Date:2013
Country:España
Institution:Universidad de Navarra
Repository:Dadun. Depósito Académico Digital de la Universidad de Navarra
Language:English
OAI Identifier:oai:dadun.unav.edu:10171/34786
Online Access:https://hdl.handle.net/10171/34786
Access Level:Open access
Keyword:Breast cancer
MCF7
Lipid nanoparticles
Edelfosine
Alkylphospholipids
id ES_18e57c3fc7ed2dc73316ea3100fcda00
oai_identifier_str oai:dadun.unav.edu:10171/34786
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy of edelfosine lipid nanoparticles in breast cancer cellsAznar, M.A. (María Ángela)|||/items/8a93c205-a638-4589-8774-64166348f62cLasa-Saracibar, B. (Beatriz)|||/items/01d03220-3bc2-4e01-8b38-247a935720cdEstella-Hermoso-de-Mendoza, A. (Ander)|||/items/a707a792-b20f-4871-9546-bd9aff90b5c5Blanco-Prieto, M.J. (María José)|||/items/93e177db-635f-456f-b672-b79ef8befc40Breast cancerMCF7Lipid nanoparticlesEdelfosineAlkylphospholipidsBreast cancer is a heterogeneous group of neoplasms predominantly originating in the terminal duct lobular units. It represents the leading cause of cancer death in women and the survival frequencies for patients at advanced stages of the disease remain low. New treatment options need to be researched to improve these rates. The anti-tumor ether lipid edelfosine (ET) is the prototype of a novel generation of promising anticancer drugs. However, it presents several drawbacks for its use in cancer therapy, including gastrointestinal and hemolytic toxicity and low oral bioavailability. To overcome these obstacles, ET was encapsulated in Precirol ATO 5 lipid nanoparticles (ET-LN), and its anti-tumor potential was in vitro tested in breast cancer. The formulated ET-LN were more effective in inhibiting cell proliferation and notably decreased cell viability, showing that the cytotoxic effect of ET was considerably enhanced when ET was encapsulated. In addition, ET and ET-LN were able to promote cell cycle arrest at G1 phase. Moreover, although both treatments provoked an apoptotic effect in a time-dependent manner, such anti-tumor effects were noticeably improved with ET-LN treatment. Therefore, our results indicate that encapsulating ET in LN played an essential role in improving the efficacy of the drug.ElsevierDadun. Depósito Académico Digital Universidad de Navarra20132013-12-2320132013-01-0120132013-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttps://hdl.handle.net/10171/34786reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/347862026-06-21T12:47:57Z
dc.title.none.fl_str_mv Efficacy of edelfosine lipid nanoparticles in breast cancer cells
title Efficacy of edelfosine lipid nanoparticles in breast cancer cells
spellingShingle Efficacy of edelfosine lipid nanoparticles in breast cancer cells
Aznar, M.A. (María Ángela)|||/items/8a93c205-a638-4589-8774-64166348f62c
Breast cancer
MCF7
Lipid nanoparticles
Edelfosine
Alkylphospholipids
title_short Efficacy of edelfosine lipid nanoparticles in breast cancer cells
title_full Efficacy of edelfosine lipid nanoparticles in breast cancer cells
title_fullStr Efficacy of edelfosine lipid nanoparticles in breast cancer cells
title_full_unstemmed Efficacy of edelfosine lipid nanoparticles in breast cancer cells
title_sort Efficacy of edelfosine lipid nanoparticles in breast cancer cells
dc.creator.none.fl_str_mv Aznar, M.A. (María Ángela)|||/items/8a93c205-a638-4589-8774-64166348f62c
Lasa-Saracibar, B. (Beatriz)|||/items/01d03220-3bc2-4e01-8b38-247a935720cd
Estella-Hermoso-de-Mendoza, A. (Ander)|||/items/a707a792-b20f-4871-9546-bd9aff90b5c5
Blanco-Prieto, M.J. (María José)|||/items/93e177db-635f-456f-b672-b79ef8befc40
author Aznar, M.A. (María Ángela)|||/items/8a93c205-a638-4589-8774-64166348f62c
author_facet Aznar, M.A. (María Ángela)|||/items/8a93c205-a638-4589-8774-64166348f62c
Lasa-Saracibar, B. (Beatriz)|||/items/01d03220-3bc2-4e01-8b38-247a935720cd
Estella-Hermoso-de-Mendoza, A. (Ander)|||/items/a707a792-b20f-4871-9546-bd9aff90b5c5
Blanco-Prieto, M.J. (María José)|||/items/93e177db-635f-456f-b672-b79ef8befc40
author_role author
author2 Lasa-Saracibar, B. (Beatriz)|||/items/01d03220-3bc2-4e01-8b38-247a935720cd
Estella-Hermoso-de-Mendoza, A. (Ander)|||/items/a707a792-b20f-4871-9546-bd9aff90b5c5
Blanco-Prieto, M.J. (María José)|||/items/93e177db-635f-456f-b672-b79ef8befc40
author2_role author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv Breast cancer
MCF7
Lipid nanoparticles
Edelfosine
Alkylphospholipids
topic Breast cancer
MCF7
Lipid nanoparticles
Edelfosine
Alkylphospholipids
description Breast cancer is a heterogeneous group of neoplasms predominantly originating in the terminal duct lobular units. It represents the leading cause of cancer death in women and the survival frequencies for patients at advanced stages of the disease remain low. New treatment options need to be researched to improve these rates. The anti-tumor ether lipid edelfosine (ET) is the prototype of a novel generation of promising anticancer drugs. However, it presents several drawbacks for its use in cancer therapy, including gastrointestinal and hemolytic toxicity and low oral bioavailability. To overcome these obstacles, ET was encapsulated in Precirol ATO 5 lipid nanoparticles (ET-LN), and its anti-tumor potential was in vitro tested in breast cancer. The formulated ET-LN were more effective in inhibiting cell proliferation and notably decreased cell viability, showing that the cytotoxic effect of ET was considerably enhanced when ET was encapsulated. In addition, ET and ET-LN were able to promote cell cycle arrest at G1 phase. Moreover, although both treatments provoked an apoptotic effect in a time-dependent manner, such anti-tumor effects were noticeably improved with ET-LN treatment. Therefore, our results indicate that encapsulating ET in LN played an essential role in improving the efficacy of the drug.
publishDate 2013
dc.date.none.fl_str_mv 2013
2013-12-23
2013
2013-01-01
2013
2013-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/34786
url https://hdl.handle.net/10171/34786
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404013195165696
score 15.301603

Similar Items